TAK - Takeda Pharmaceutical Company Limited
NYSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Tokyo,
Japan
Type: Equity
TAK price evolution
TAK
| (in millions $) | 1 May 2025 | 30 Oct 2024 | 30 Jul 2024 | 1 Feb 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $410687.39 | $277613.76 | ||
| Short term investments | $165032.1 | $200670.89 | ||
| Net receivables | $721056 | $625818.33 | $715389.33 | |
| Inventory | $1206431 | $1085360.3 | $1126055.21 | |
| Total current assets | $3054013 | $2295274.24 | $2338322.52 | |
| Long term investments | $11258659.36 | $11354628.82 | ||
| Property, plant & equipment | $1887620 | $1785007.27 | $1772878.45 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $14573000 | $13553933.6 | $13692951.34 | |
| Current liabilities | ||||
| Accounts payable | $413335 | $491175.12 | $465642.95 | |
| Deferred revenue | ||||
| Short long term debt | $458118.29 | $595348.6 | ||
| Total current liabilities | $2387237 | $2075059.5 | $2197126.61 | |
| Long term debt | $4427092 | $4632867.77 | $4655792.17 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $7652246 | $7029167.7 | $7202244.86 | |
| Shareholders' equity | ||||
| Retained earnings | $1431684 | $1248033.06 | $1344787.04 | |
| Other shareholder equity | $2081094 | $3061544 | $2509310 | |
| Total shareholder equity | $6524765.9 | $6490707.44 | ||
| (in millions $) | 28 Jun 2023 | 29 Jun 2022 | 1 May 2022 | 31 Mar 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $545648.18 | $941341.81 | $849695 | $9082.49 |
| Short term investments | $185154.05 | $184352.08 | $330.52 | |
| Net receivables | $697176.44 | $802507.2 | $724377 | $7639.51 |
| Inventory | $1008863.63 | $945187.19 | $853167 | $6808.34 |
| Total current assets | $2452423.33 | $2873388.28 | $2593642 | $24500.29 |
| Long term investments | $11822354.06 | $11725990.68 | $96579 | $3145.97 |
| Property, plant & equipment | $1729642.24 | $1753518.4 | $1582800 | $13666.82 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $95874.37 | |||
| Total investments | ||||
| Total assets | $14274777.4 | $14599378.96 | $13178018 | $116611.66 |
| Current liabilities | ||||
| Accounts payable | $663979.17 | $571984.01 | $516297 | $3105.22 |
| Deferred revenue | ||||
| Short long term debt | $537064.55 | $443214.29 | $203708 | $22153 |
| Total current liabilities | $2538312.83 | $2377165.17 | $2145730 | $16013.65 |
| Long term debt | $4680968.6 | $5107627.52 | $4141418 | $41662.24 |
| Total noncurrent liabilities | $56042.24 | |||
| Total debt | $46537.47 | |||
| Total liabilities | $7776331.85 | $8303399.29 | $7494999 | $69856.28 |
| Shareholders' equity | ||||
| Retained earnings | $1576150.38 | $1639315.92 | $1479716 | $13636.05 |
| Other shareholder equity | $2493581 | $1495649 | $934174 | $3306.4 |
| Total shareholder equity | $6498445.55 | $6295979.67 | $5683019 | $5173037 |
| (in millions $) | 30 Jul 2025 | 1 May 2025 | 30 Oct 2024 | 30 Jul 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | ||||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | ||||
| Income (for common shares) | ||||
| (in millions $) | 28 Jun 2023 | 29 Jun 2022 | 1 May 2022 | 1 May 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4118954.97 | $3953953.55 | $3569006 | $30059.43 |
| Cost of revenue | $1272328.87 | $1226228.72 | $994308 | |
| Gross Profit | $2846626.09 | $2727724.83 | $2462160 | $20712.94 |
| Operating activities | ||||
| Research & development | $647709.85 | $582829.94 | $456133 | |
| Selling, general & administrative | $1019961.09 | $981962.55 | $873763 | |
| Total operating expenses | $3507253.83 | $3341113.94 | $2001316 | $15926.3 |
| Operating income | $611701.14 | $612839.61 | $4787.13 | |
| Income from continuing operations | ||||
| EBIT | $611701.14 | $612839.61 | $389369 | |
| Income tax expense | $59370.55 | $80214.49 | $72405 | -$93.4 |
| Interest expense | -$158274 | $2337.13 | ||
| Net income | ||||
| Net income | $324217.47 | $255108.79 | $230059 | $3534.45 |
| Income (for common shares) | $324217.47 | $255108.79 | $376005 | |
| (in millions $) | 30 Oct 2024 | 26 Jun 2024 | 1 Feb 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | -$12757.83 | $101780.51 | ||
| Operating activities | ||||
| Depreciation | $131993.79 | $199152.11 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $221178.76 | $156671.76 | ||
| Investing activities | ||||
| Capital expenditures | -$30370.28 | -$92508.96 | ||
| Investments | ||||
| Total cash flows from investing | -$231824 | -$28742.56 | -$90065.24 | -$402378 |
| Financing activities | ||||
| Dividends paid | -$147309 | -$278062 | ||
| Sale and purchase of stock | ||||
| Net borrowings | $4515266.57 | $4772856.13 | ||
| Total cash flows from financing | $206336 | -$32786.96 | -$104796.04 | -$296193 |
| Effect of exchange rate | -$24564 | $15644 | ||
| Change in cash and equivalents | $401215 | $410687.39 | $277613.76 | -$245171 |
| (in millions $) | 28 Jun 2023 | 29 Jun 2022 | 1 May 2022 | 1 May 2021 |
|---|---|---|---|---|
| Net income | $324217.47 | $255108.79 | $3536.01 | |
| Operating activities | ||||
| Depreciation | $679490.66 | $646048.78 | $559671 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $999351.38 | $1244243.61 | $9502.75 | |
| Investing activities | ||||
| Capital expenditures | -$648082.11 | -$206102.67 | -$111206 | |
| Investments | $62008 | |||
| Total cash flows from investing | -$620891.24 | -$219495.57 | -$198125 | $3699.18 |
| Financing activities | ||||
| Dividends paid | -$283665 | -$2663.56 | ||
| Sale and purchase of stock | ||||
| Net borrowings | $4487230.93 | $4425147.92 | -$660504 | |
| Total cash flows from financing | -$725256.05 | -$1185702.15 | -$1070265 | -$10230.53 |
| Effect of exchange rate | $28758 | $117.51 | ||
| Change in cash and equivalents | -$398196.07 | -$238792.86 | -$116527 | $3088.91 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.20 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |